Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer (PRIMM)

This study has been terminated.
(Recruitment difficulties)
Information provided by (Responsible Party):
Gustave Roussy, Cancer Campus, Grand Paris Identifier:
First received: October 24, 2012
Last updated: February 9, 2016
Last verified: February 2016
The purpose of this study is to analyze the clinical tolerance of immediate preoperative chemotherapy in terms of toxicity and perioperative morbidity and mortality

Condition Intervention Phase
Patients With Colorectal Cancer With Unresectable Synchronous Metastasis in Whom Resection of the Primitive Tumour is Indicated
Drug: Oxaliplatin
Drug: Folinic Acid
Drug: Fluorouracile
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Feasibility of an Immediate Preoperative Chemotherapy Before Resection of Colorectal Cancer and Research of Gene Expressions Changes Induced in the Tumor, Predictive of Chemotherapy Efficiency

Resource links provided by NLM:

Further study details as provided by Gustave Roussy, Cancer Campus, Grand Paris:

Primary Outcome Measures:
  • Clinical tolerance of immediate preoperative chemotherapy [ Time Frame: Assess up to 30 days after surgery ]

    Clinical tolerance of immediate preoperative chemotherapy assessment is based on the post-operative complication rate in terms of morbidity and mortality.

    All the post-operative complications arising within 30 days after surgery will be registered and classified using the Clavien Dindo classification

Enrollment: 3
Study Start Date: July 2012
Study Completion Date: June 2014
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: FOLFOX + surgery + FOLFOX
  • Systemic chemotherapy (modified FOLFOX 4) 48 hours before surgery
  • resection of the colorectal tumor during surgery
  • Resumption of FOLFOX within the month after surgery (post operative administration of 4 course of treatment and assessment of the response)
Drug: Oxaliplatin Drug: Folinic Acid Drug: Fluorouracile


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • colorectal metastatic adenocarcinoma (stage IV) with unresectables, measurables and visibles secondary lesions
  • primitive tumor must be operate
  • patient age between 18 and 70
  • OMS status performance < 2
  • life expectancy > 12 weeks
  • hematologic function : PNN >/= 1.5x10^9/L, platelets >/= 100x10^9/L
  • hepatic function : bilirubin </= 1.5xLSN, AST and ALT </= 3xLSN, alcalin phosphatasis </= 3xLSN
  • plasmatimic creatin </= 1.25xLSN
  • No previous chemotherapy or pelvic radiotherapy
  • men and women in age of procreate agreeing to use a contraception until 4 months after the end of treatment for women and until 6 months for men

Exclusion Criteria:

  • nonmetastatic forms
  • Colorectal tumor which requires preoperative radiotherapy
  • nonmeasurable metastasis based on RECIST criteria
  • previous chemotherapy for colorectal cancer
  • previous irradiation of the primitive tumour
  • specific indication against the treatment studied
  • Patient considered as inoperable for physiological or carcinologic reasons
  • Pregnant or breast feeding women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01715363

Institut Gustave Roussy
Villejuif, Val de Marne, France, 94805
Sponsors and Collaborators
Gustave Roussy, Cancer Campus, Grand Paris
Principal Investigator: Diane GOERE, MD Gustave Roussy, Cancer Campus, Grand Paris
  More Information

Responsible Party: Gustave Roussy, Cancer Campus, Grand Paris Identifier: NCT01715363     History of Changes
Other Study ID Numbers: 2011-003446-41
2010/1676 ( Other Identifier: Institut Gustave Roussy )
Study First Received: October 24, 2012
Last Updated: February 9, 2016

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Folic Acid
Antineoplastic Agents
Protective Agents
Physiological Effects of Drugs
Vitamin B Complex
Growth Substances
Hematinics processed this record on May 25, 2017